MGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Metagenomi Therapeutics Inc (MGX) is not a strong buy for a beginner, long-term investor at this time. The company's financials show declining revenue and negative net income, hedge funds are selling heavily, and there are no strong technical or proprietary trading signals to support immediate action. The stock is better suited for monitoring rather than immediate investment.
The MACD is positive and expanding, indicating a bullish trend. However, the RSI is in the neutral zone at 71.337, and moving averages are converging, suggesting no strong directional momentum. Key support and resistance levels are close to the current pre-market price of 1.41, with a pivot at 1.381.
MACD histogram is positive and expanding, indicating potential bullish momentum.
Hedge funds are selling heavily, with a 323.12% increase in selling activity last quarter. Financials show declining revenue (-24.80% YoY) and negative net income, although slightly improved YoY. News of a fiduciary investigation could negatively impact investor confidence.
In Q3 2025, revenue dropped significantly by -24.80% YoY to $8,659,000. Net income remains negative at -$20,393,000, though it improved by 8.63% YoY. EPS also remains negative at -0.55, with a slight improvement of 7.84% YoY. Gross margin remains flat at 100%.
No recent analyst rating or price target changes available.
